152 related articles for article (PubMed ID: 27520727)
1. Nanocarriers in cancer clinical practice: a pharmacokinetic issue.
Giodini L; Re FL; Campagnol D; Marangon E; Posocco B; Dreussi E; Toffoli G
Nanomedicine; 2017 Feb; 13(2):583-599. PubMed ID: 27520727
[TBL] [Abstract][Full Text] [Related]
2. Improved chemical strategies for the targeted therapy of cancer.
Maison W; Frangioni JV
Angew Chem Int Ed Engl; 2003 Oct; 42(39):4726-8. PubMed ID: 14562338
[No Abstract] [Full Text] [Related]
3. A structure-property relationship study of the well-defined telodendrimers to improve hemocompatibility of nanocarriers for anticancer drug delivery.
Shi C; Yuan D; Nangia S; Xu G; Lam KS; Luo J
Langmuir; 2014 Jun; 30(23):6878-88. PubMed ID: 24849780
[TBL] [Abstract][Full Text] [Related]
4. [Hybrid nanocarriers for controlled delivery of antitumour and retroviral drugs delivery].
Horcajada P; Serre C; Férey G; Couvreur P; Gref R
Med Sci (Paris); 2010; 26(8-9):761-7. PubMed ID: 20819715
[TBL] [Abstract][Full Text] [Related]
5. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.
Agarwal A; Mackey MA; El-Sayed MA; Bellamkonda RV
ACS Nano; 2011 Jun; 5(6):4919-26. PubMed ID: 21591812
[TBL] [Abstract][Full Text] [Related]
6. Emerging nanotherapeutic strategies in breast cancer.
Blanco E; Ferrari M
Breast; 2014 Feb; 23(1):10-8. PubMed ID: 24215984
[TBL] [Abstract][Full Text] [Related]
7. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
9. Apoferritin as an ubiquitous nanocarrier with excellent shelf life.
Dostalova S; Vasickova K; Hynek D; Krizkova S; Richtera L; Vaculovicova M; Eckschlager T; Stiborova M; Heger Z; Adam V
Int J Nanomedicine; 2017; 12():2265-2278. PubMed ID: 28392686
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs.
Iwamoto T
Biol Pharm Bull; 2013; 36(5):715-8. PubMed ID: 23649331
[TBL] [Abstract][Full Text] [Related]
12. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
13. Advances in the use of nanocarriers for cancer diagnosis and treatment.
Vieira DB; Gamarra LF
Einstein (Sao Paulo); 2016; 14(1):99-103. PubMed ID: 27074238
[TBL] [Abstract][Full Text] [Related]
14. Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells.
Tarvirdipour S; Vasheghani-Farahani E; Soleimani M; Bardania H
Int J Pharm; 2016 Mar; 501(1-2):331-41. PubMed ID: 26875475
[TBL] [Abstract][Full Text] [Related]
15. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs.
Fanciullino R; Ciccolini J; Milano G
Crit Rev Oncol Hematol; 2013 Dec; 88(3):504-13. PubMed ID: 23871532
[TBL] [Abstract][Full Text] [Related]
16. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
17. Dextran-based doxorubicin nanocarriers with improved tumor penetration.
Sagnella SM; Duong H; MacMillan A; Boyer C; Whan R; McCarroll JA; Davis TP; Kavallaris M
Biomacromolecules; 2014 Jan; 15(1):262-75. PubMed ID: 24313925
[TBL] [Abstract][Full Text] [Related]
18. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment.
Feng T; Tian H; Xu C; Lin L; Xie Z; Lam MH; Liang H; Chen X
Eur J Pharm Biopharm; 2014 Nov; 88(3):1086-93. PubMed ID: 25305583
[TBL] [Abstract][Full Text] [Related]
19. An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform.
Wang W; Song H; Zhang J; Li P; Li C; Wang C; Kong D; Zhao Q
J Control Release; 2015 Apr; 203():57-66. PubMed ID: 25683618
[TBL] [Abstract][Full Text] [Related]
20. Injectable poly(organophosphazene) hydrogel system for effective paclitaxel and doxorubicin combination therapy.
Cho JK; Kuh HJ; Song SC
J Drug Target; 2014 Sep; 22(8):761-7. PubMed ID: 24937548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
